To hear about similar clinical trials, please enter your email below
Trial Title:
Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
NCT ID:
NCT05752669
Condition:
Papillary Thyroid Cancer
Conditions: Official terms:
Thyroid Neoplasms
Thyroid Cancer, Papillary
Thyroid Diseases
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
Oxidative stress (OS) could be involved in the progression of papillary thyroid cancer
(PTC). Indeed, thyroid differentiation genes are silenced by a mechanism controlled by
NOX4-derived OS. On the other hand, TERT contributes to mitochondrial OS protection,
which could increase the resistance of cancer cells to therapeutic agents. The
investigators aim to address the role of OS and mitochondrial TERT in the progression and
therapeutic resistance of PTC. OS and TERT subcellular localization will be investigated
in 150 PTCs and correlated to the genetic and expression profile of the tumors and to the
clinical and prognostic features of the patients. Mechanisms implicated in TERT
mitochondrial migration and the contribution of mitochondrial TERT to tumor progression
will be investigated in cancer cell lines and primary cell cultures. This study will
allow to identify OS as a marker of therapeutic resistance in PTC and will open new
opportunities for the development of novel treatments targeting ROS generation/TERT
nuclear export.
Criteria for eligibility:
Study pop:
Patients operated for papillary thyroid cancer and followed by our Center of Excellence
for the Diagnosis and Treatment of Thyroid Tumors.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients with papillary thyroid cancer
- Patients whose tumor and contralateral healthy tissues can be collected for the
analyses
Exclusion Criteria:
- patients who did not provide consent
- patients lost at follow-up
- tissues not adequate for the analyses
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Istituto Auxologico Italiano
Address:
City:
Milan
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Marina Muzza, PhD
Start date:
September 15, 2021
Completion date:
May 31, 2024
Lead sponsor:
Agency:
Istituto Auxologico Italiano
Agency class:
Other
Source:
Istituto Auxologico Italiano
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05752669
https://pubmed.ncbi.nlm.nih.gov/27164443/
https://pubmed.ncbi.nlm.nih.gov/29214440/
https://pubmed.ncbi.nlm.nih.gov/25417114/
https://pubmed.ncbi.nlm.nih.gov/26462967/
https://pubmed.ncbi.nlm.nih.gov/30867499/
